Dow Chemical, Kereos, and Royal Philips Electronics (parent company of Philips Medical Systems) are collaborators in a $2.8-million, three-year contract awarded by the National Cancer Institute (NCI) to Barnes-Jewish Hospital (BJH) and Washington University School of Medicine in St. Louis. The contract is for the development and testing of molecular imaging agents to enable earlier, noninvasive detection of some cancers.
Washington University researchers at BJH will collaborate with Philips and Dow to create and evaluate contrast and therapeutic agents designed to seek out specific molecular targets for the purpose of diagnosing and treating cancers. Kereos will be responsible for development and commercialization of promising agents discovered through the contract. Initial data from the project is expected by early 2004, NCI said.
By AuntMinnie.com staff writersApril 25, 2003
Related Reading
Merger savings boosts Philips Medical’s bottom line, April 17, 2003
Philips boosts cardiac offerings, April 1, 2003
Philips hires new senior executives, March 31, 2003
Philips debuts lung nodule assessment option, March 7, 2003
Acquisitions drive Philips Medical growth, February 12, 2003
Copyright © 2003 AuntMinnie.com
